Mylan Provides Statement in Response to Announcement of Proposed Amendments to Civil Complaint
October 31 2017 - 12:00PM
PR Newswire (US)
HERTFORDSHIRE, England and
PITTSBURGH, Oct. 31, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ,
TASE: MYL) provided the following statement in response to the
announcement of proposed amendments to the civil complaint by
various states' attorneys general in multi-district litigation
pending in the U.S. District Court for the Eastern District of
Pennsylvania against Mylan and 17
other pharmaceutical companies:
We have been investigating these allegations thoroughly and have
found no evidence of price fixing on the part of Mylan or its
employees. Our review of the Connecticut Attorney General's press release
underpinning the complaint does not change our views. We have asked
the various attorneys general leading this case to share with us
what information they believe supports these new allegations and,
to date, they have not done so. Mylan has deep faith in the
integrity of its President, Rajiv
Malik, and stands behind him fully. Mylan and Rajiv Malik both intend to defend this
case vigorously, and we look forward to the opportunity to present
a full defense.
Mylan takes its legal obligations seriously and operates with
the highest levels of integrity and character. Mylan expects to
have no further comment while the matter is pending.
View original
content:http://www.prnewswire.com/news-releases/mylan-provides-statement-in-response-to-announcement-of-proposed-amendments-to-civil-complaint-300546473.html
SOURCE Mylan N.V.
Copyright 2017 PR Newswire
Mylan NV (NASDAQ:MYL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Mylan NV (NASDAQ:MYL)
Historical Stock Chart
From Sep 2023 to Sep 2024